COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	1 Months Ended				3 Months Ended		6 Months Ended		12 Months Ended
	Aug. 31, 2021	Jul. 31, 2021	Dec. 31, 2019	Apr. 30, 2017	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Klarity License Agreement [Member]
Loss Contingencies [Line Items]
Milestone payment in cash					$ 92,000	$ 35,000	$ 122,000	$ 70,000
Royalty expense					106,000	44,000	177,000	79,000
Klarity License Agreement [Member] | Richard L. Lindstrom, M.D [Member]
Loss Contingencies [Line Items]
Royalty payment description				Under the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% to 6% of net sales, dependent upon the final formulation of the Klarity Product sold
Injectable Asset Purchase Agreement [Member]
Loss Contingencies [Line Items]
Milestone payment in cash					7,000	7,000	15,000	14,000
Royalty expense					8,000	7,000	$ 15,000	14,000
Injectable Asset Purchase Agreement [Member] | Richard L. Lindstrom, M.D [Member]
Loss Contingencies [Line Items]
Royalty payment description			the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net sales, dependent upon the final formulation and patent protection of the Lindstrom Product sold
Initial milestone payment			$ 33,000
Dexycu Agreement [Member]
Loss Contingencies [Line Items]
Expiration date							Aug. 01, 2025
Commission revenues					1,212,000	827,000	$ 2,532,000	1,312,000
Sales and Marketing Agreements [Member]
Loss Contingencies [Line Items]
Description for commission payments							Under the terms of the sales and marketing agreements, the Company is generally required to make commission payments equal to 10% to 14% of net sales for products above and beyond the initial existing sales amounts
Commission expenses					1,100,000	1,032,000	$ 2,147,000	1,836,000
Sales and Marketing Agreements [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Commission payments percentage							10.00%
Sales and Marketing Agreements [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Commission payments percentage							14.00%
Asset Purchase, License and Related Agreements [Member]
Loss Contingencies [Line Items]
Royalty expense					297,000	261,000	$ 510,000	493,000
Sintetica Agreement [Member]
Loss Contingencies [Line Items]
Payment for royalties		$ 18,000,000
Sintetica Agreement [Member] | Research and Development Expense [Member]
Loss Contingencies [Line Items]
Payment for royalties									$ 3,117,000
Sintetica Agreement [Member] | Due Within Thirty Days [Member]
Loss Contingencies [Line Items]
Payment for royalties		$ 5,000,000
Wakamoto Agreement [Member]
Loss Contingencies [Line Items]
Payment for royalties	$ 2,000,000
Commercial payments for royalties	$ 6,200,000
Presbyopia Asset Purchase Agreement [Member]
Loss Contingencies [Line Items]
Milestone payment in cash					0	0	0	0
Royalty expense					0	0	0	0
Milestone payment in cash					$ 0	$ 0	$ 0	$ 0
Presbyopia Asset Purchase Agreement [Member] | Richard L. Lindstrom, M.D [Member]
Loss Contingencies [Line Items]
Royalty payment description			the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 4% of net sales, dependent upon the final formulation and patent protection of the Presbyopia Product sold